Changes in the core of the mammalian-pyruvate dehydrogenase complex upon selective removal of the lipoyl domain from the transacetylase component but not from the protein X component
- PMID: 2167319
Changes in the core of the mammalian-pyruvate dehydrogenase complex upon selective removal of the lipoyl domain from the transacetylase component but not from the protein X component
Abstract
The dihydrolipoyl transacetylase (E2) component contains a COOH-terminal inner domain (E2I) and an extended NH2-terminal structure, which is composed of two lipoyl domains (the fragment containing both is designated as E2L) and a subunit-binding domain (E2B). The four domains are connected by hinge regions. A subcomplex, composed of an oligomer of E2 subunits, protein X (which also has an NH2-terminal lipoyl domain), and the [pyruvate dehydrogenase]-kinase catalytic and basic subunits (Kc and Kb, respectively) (i.e. E2.X.KcKb subcomplex), was treated with Clostridium histolyticum collagenase. E2 subunits were selectively cleaved at the NH2-terminal end of the E2B domain, releasing the E2L fragment. Complete release of E2 subunits also released the kinase subunits, indicating that the kinase is bound to the E2L portion of E2. The residual inner core subcomplex (designated E2IB.X) has a strong tendency to aggregate, but this can be reversed with heparin (1 mg/ml). The E2IB.X subcomplex binds the pyruvate dehydrogenase (E1) and dihydrolipoyl dehydrogenase (E3) components. The E1 component, which binds to the E2B domain, blocked collagenase cleavage of E2. We evaluated the capacity of the collagenase-treated E2.X.KcKb subcomplex, from which different portions of the E2L domains were removed, to support (in combination with excess levels of the E1 and E3 components) the overall reaction of the complex. Loss of activity occurred only after more than half of the E2L domains were removed. This delay is in sharp contrast to the effect of selective removal of the lipoyl domain of protein X, which leads to an immediate decrease in activity (Gopalakrishnan, S., Rahmatullah, M., Radke, G.-A., Powers-Greenwood, S. L., and Roche, T. E. (1989) Biochem. Biophys. Res. Commun. 160, 715-721). These results suggest that multiple lipoyl domains of the E2 component service the rate-limiting E1 component. After all the E2L domains were removed and the E2IB.X subcomplex was separated from free E2L, 10% activity was retained in the overall reaction. Thus, the lipoyl domain of protein X supported the overall reaction of the complex.
Similar articles
-
Additional binding sites for the pyruvate dehydrogenase kinase but not for protein X in the assembled core of the mammalian pyruvate dehydrogenase complex: binding region for the kinase.Arch Biochem Biophys. 1992 Aug 1;296(2):497-504. doi: 10.1016/0003-9861(92)90603-t. Arch Biochem Biophys. 1992. PMID: 1321586
-
Subunit associations in the mammalian pyruvate dehydrogenase complex. Structure and role of protein X and the pyruvate dehydrogenase component binding domain of the dihydrolipoyl transacetylase component.J Biol Chem. 1989 Feb 5;264(4):2221-7. J Biol Chem. 1989. PMID: 2914903
-
Binding of the pyruvate dehydrogenase kinase to recombinant constructs containing the inner lipoyl domain of the dihydrolipoyl acetyltransferase component.J Biol Chem. 1995 Jan 13;270(2):793-800. doi: 10.1074/jbc.270.2.793. J Biol Chem. 1995. PMID: 7822313
-
The pyruvate dehydrogenase multi-enzyme complex from Gram-negative bacteria.Biochim Biophys Acta. 1998 Jun 29;1385(2):353-66. doi: 10.1016/s0167-4838(98)00079-x. Biochim Biophys Acta. 1998. PMID: 9655933 Review.
-
Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview.2015 Oct 1 [updated 2025 May 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2015 Oct 1 [updated 2025 May 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 26425749 Free Books & Documents. Review.
Cited by
-
Inhibition by methylated organo-arsenicals of the respiratory 2-oxo-acid dehydrogenases.J Organomet Chem. 2009 Mar 15;694(6):973-980. doi: 10.1016/j.jorganchem.2008.12.028. J Organomet Chem. 2009. PMID: 20161290 Free PMC article.
-
Heterologously expressed inner lipoyl domain of dihydrolipoyl acetyltransferase inhibits ATP-dependent inactivation of pyruvate dehydrogenase complex. Identification of important amino acid residues.Biochem J. 1998 Sep 15;334 ( Pt 3)(Pt 3):703-11. doi: 10.1042/bj3340703. Biochem J. 1998. PMID: 9729480 Free PMC article.
-
Structures of the human pyruvate dehydrogenase complex cores: a highly conserved catalytic center with flexible N-terminal domains.Structure. 2008 Jan;16(1):104-14. doi: 10.1016/j.str.2007.10.024. Structure. 2008. PMID: 18184588 Free PMC article.
-
Purification of the pyruvate dehydrogenase multienzyme complex of Zymomonas mobilis and identification and sequence analysis of the corresponding genes.J Bacteriol. 1998 Mar;180(6):1540-8. doi: 10.1128/JB.180.6.1540-1548.1998. J Bacteriol. 1998. PMID: 9515924 Free PMC article.
-
Protein lipoylation: an evolutionarily conserved metabolic regulator of health and disease.Curr Opin Chem Biol. 2018 Feb;42:76-85. doi: 10.1016/j.cbpa.2017.11.003. Epub 2017 Nov 21. Curr Opin Chem Biol. 2018. PMID: 29169048 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources